STOCK INFORMATION
PCYC - (NASDAQ)
Mar 9, 2010
at 4:00 PM ET
| Last Sale | $5.32 |
| Change Net | - 0.43 |
| Change % |  7.48% |
| Share Volume | 1,018,300 |
| More Information » | |
SHAREHOLDER TOOLS
Shareholder Briefcase |
 Investor Kit |
 News and Event Alerts |
 Download Library |
To Pharmacyclics' knowledge, all press releases and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. Pharmacyclics has no intention of updating this information, and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see the disclaimer for this website.
ABOUT PHARMACYCLICSPharmacyclics, Inc. (Nasdaq: PCYC) is a pharmaceutical company developing innovative products for cancer and immune mediated diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways, and mechanisms. The company's products address large markets in oncology and autoimmune diseases. The company is developing several product opportunities derived from structure-based research, including cancer drugs called motexafin gadolinium, histone deacetylase (HDAC) inhibitors, a Factor VIIa inhibitor, which appears to be a novel inhibitor of angiogenesis with potential applications in cancer, and tyrosine kinase inhibitors targeting lymphomas and autoimmune disorders. The company owns the worldwide rights to its drug candidates.
Recent Releases
Feb 26, 2010
Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
Feb 11, 2010
Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results
Events
 |
Mar 2, 2010 | RBC Capital Markets Healthcare Conference Panel Discussion |
|
Feb 11, 2010 | Second Quarter Fiscal 2010 Financial Results Conference Call |